| Literature DB >> 26973105 |
Michelle K Lupton1, Lachlan Strike2, Narelle K Hansell2, Wei Wen3, Karen A Mather3, Nicola J Armstrong4, Anbupalam Thalamuthu3, Katie L McMahon5, Greig I de Zubicaray6, Amelia A Assareh3, Andrew Simmons7, Petroula Proitsi7, John F Powell7, Grant W Montgomery8, Derrek P Hibar9, Eric Westman10, Magda Tsolaki11, Iwona Kloszewska12, Hilkka Soininen13, Patrizia Mecocci14, Bruno Velas15, Simon Lovestone16, Henry Brodaty3, David Ames17, Julian N Trollor3, Nicholas G Martin8, Paul M Thompson9, Perminder S Sachdev3, Margaret J Wright18.
Abstract
Reduction in hippocampal and amygdala volume measured via structural magnetic resonance imaging is an early marker of Alzheimer's disease (AD). Whether genetic risk factors for AD exert an effect on these subcortical structures independent of clinical status has not been fully investigated. We examine whether increased genetic risk for AD influences hippocampal and amygdala volumes in case-control and population cohorts at different ages, in 1674 older (aged >53 years; 17% AD, 39% mild cognitive impairment [MCI]) and 467 young (16-30 years) adults. An AD polygenic risk score combining common risk variants excluding apolipoprotein E (APOE), and a single nucleotide polymorphism in TREM2, were both associated with reduced hippocampal volume in healthy older adults and those with MCI. APOE ε4 was associated with hippocampal and amygdala volume in those with AD and MCI but was not associated in healthy older adults. No associations were found in young adults. Genetic risk for AD affects the hippocampus before the clinical symptoms of AD, reflecting a neurodegenerative effect before clinical manifestations in older adults.Entities:
Keywords: APOE; Alzheimer's disease; Amygdala; Hippocampus; Polygenic risk score; TREM2
Mesh:
Substances:
Year: 2016 PMID: 26973105 PMCID: PMC4883003 DOI: 10.1016/j.neurobiolaging.2015.12.023
Source DB: PubMed Journal: Neurobiol Aging ISSN: 0197-4580 Impact factor: 4.673